Alaya.bio
France - VillejuifBiotechnology
Focus: Alaya.bio is a pre-revenue biotechnology company developing a proprietary polymeric nanoparticle CAR T immunotherapy platform targeting oncology and cell therapy applications. The company operates as a small, focused R&D organization of 1–50 employees based in Villejuif, France.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Employees
1-50
Open Jobs
1
Should You Work at Alaya.bio?
AI assessmentAlaya.bio suits early-career scientists and technologists seeking maximum technical autonomy and platform-building experience in cell therapy, with corresponding acceptance of funding and execution risk.
Why Work Here
- Opportunity to own deep technical responsibilities in an early-stage platform company focused on next-generation cell therapy with differentiated nanoparticle delivery.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Open Jobs (1)
Interview Prep Quick Facts
Help build intelligence for Alaya.bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.